Sequential hemofiltration-hemodiafiltration technique: all in one?
Sequential dialysis techniques (i.e. pure ultrafiltration followed by dialysis) have been used in the past, due to their capability to remove large volumes of fluids without inducing hemodynamic instability. The disadvantages of the inadequate dialysis and the lack of technology lead to the decline such methods. Hemofiltration (HF) and hemodiafiltration (HDF) are recently being utilized in a greater proportion thanks to the on line fluid preparation systems. Each process (HF and HDF) has its own benefits in the removal of small, medium and high-molecular weight substances and in the hemodynamic stability. Sequential hemofiltration/ hemodiafiltration (SHF/HDF), may combine the benefits and eliminate the disadvantages of each method. Furthermore they can be easily applied nowadays, due to the development of new high technological hemodialysis machines. In order to evaluate the feasibility and the effects of SHF/HDF we studied 7 chronic hemodialysis patients (6 months of treatment with SHF/HDF switched to 6 months of SHDF/HF), using the same machine (AK200 ULTRA), with on line fluid preparation system and the same type of dialyzer (Polyflux 210). The feasibility of such techniques (SHF/HDF or vice versa) resulted excellent. All sessions left the patients in a condition of well-being making fulltime work. No difference was observed between the different period of treatment, but a reduction in pre value was observed in calcium-phosphorous product, C-reactive protein and beta2-microglobulin, at the end of the sequential techniques. SHF/HDF therapy is a very promising technique. Further studies are needed to better explore the potential of such a therapeutic approach in the quality of life, the hemodialysis adequacy and the hemodynamic stability of our patients.
Amato
M
M
Nephrology Department, Prato Hospital, Prato, Italy.
Brendolan
A
A
Campolo
G
G
Petras
D
D
Bonello
M
M
Crepaldi
C
C
Ronco
C
C
D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism; D002118:Calcium / Q000097:blood; D018592:Cross-Over Studies; D004867:Equipment Design; D005240:Feasibility Studies; D017583:Hemodiafiltration / Q000295:instrumentation / Q000379:methods*; D006440:Hemofiltration / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D010758:Phosphorus / Q000097:blood; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000097:blood
D001613:beta 2-Microglobulin; D010758:Phosphorus; D002097:C-Reactive Protein; D002118:Calcium